Skip to main content

Starling Oncology, Inc.

STLNW
Exchange
Nasdaq
Industry
Services-Offices & Clinics of Doctors of Medicine
SEC CIK
0001799191

In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $706.5K in total; no superinvestor holds it.

Other share classesDFPHSTLN

13F holders, Q2 2022

Institutional positions in Starling Oncology, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
13
−1 vs. Q1 2022
Shares held
3.36M
+11.0K (+0.3%) vs. Q1 2022
Total value
$7.67M
−$3.56M (−31.7%) vs. Q1 2022
New holders
0
3 more added
Sold out
1
3 more reduced

Compare with Q1 2022: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting STLNW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2022: 13 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 0 institutionsQ4 2021: 22 institutionsQ1 2022: 14 institutionsQ2 2022: 13 institutionsQ3 2022: 14 institutionsQ4 2022: 14 institutionsQ1 2023: 17 institutionsQ2 2023: 15 institutionsQ3 2023: 15 institutionsQ4 2023: 16 institutionsQ1 2024: 15 institutionsQ2 2024: 18 institutionsQ3 2024: 15 institutionsQ4 2024: 14 institutionsQ1 2025: 11 institutionsQ2 2025: 11 institutionsQ3 2025: 12 institutionsQ4 2025: 11 institutionsQ1 2026: 11 institutionsQ2 2026: 12 institutions
Value heldQ2 2022: $7.67M
Q1 2021: $0Q2 2021: $0Q3 2021: $0Q4 2021: $4.18MQ1 2022: $11.2MQ2 2022: $7.67MQ3 2022: $7.36MQ4 2022: $2.77MQ1 2023: $1.30MQ2 2023: $133.5KQ3 2023: $409.0KQ4 2023: $810.2KQ1 2024: $832.5KQ2 2024: $108.0KQ3 2024: $52.0KQ4 2024: $19.2KQ1 2025: $94.9KQ2 2025: $195.4KQ3 2025: $818.0KQ4 2025: $821.1KQ1 2026: $479.4KQ2 2026: $706.5K
Institutions holding STLNW and their total value by quarter
QuarterHoldersValue
Q2 202612$706.5K
Q1 202611$479.4K
Q4 202511$821.1K
Q3 202512$818.0K
Q2 202511$195.4K
Q1 202511$94.9K
Q4 202414$19.2K
Q3 202415$52.0K
Q2 202418$108.0K
Q1 202415$832.5K
Q4 202316$810.2K
Q3 202315$409.0K
Q2 202315$133.5K
Q1 202317$1.30M
Q4 202214$2.77M
Q3 202214$7.36M
Q2 202213$7.67M
Q1 202214$11.2M
Q4 202122$4.18M
Q3 20210$0
Q2 20210$0
Q1 20210$0

Institutions, Q2 2022

Shares, value and share of portfolio for each institution holding Starling Oncology, Inc.; share changes are against Q1 2022.

Institutions holding STLNW in Q2 2022
InstitutionSharesValue% of portfolioChange in sharesAction
LMR Partners LLP1,196,386$6.05M0.11%+172,395+16.8%Added
Deerfield Management Company, L.P. (Series C)1,250,000$625.0K0.01%00.0%Unchanged
Highbridge Capital Management LLC–$529.0K0.01%––
Davidson Kempner Capital Management LP318,710$159.0K0.00%00.0%Unchanged
Union Square Park Capital Management, LLC120,000$60.0K0.07%00.0%Unchanged
Wolverine Asset Management LLC118,666$59.0K0.00%+26,700+29.0%Added
Difesa Capital Management, LP115,975$58.0K0.04%−9,025−7.2%Reduced
Jefferies Group LLC95,200$47.6K0.00%−60,257−38.8%Reduced
Healthcare of Ontario Pension Plan Trust Fund87,500$44.0K0.00%00.0%Unchanged
Alpine Global Management, LLC25,024$13.0K0.00%−25,024−50.0%Reduced
Tenor Capital Management Co., L.P.25,000$13.0K0.00%00.0%Unchanged
JPMorgan Chase & Co–$4.00K0.00%––
UBS Group AG5,474$3.00K0.00%+1,000+22.4%Added
Man Group plc0$00.00%−94,740−100.0%Sold out